Wave Life Sciences Ltd.
NASDAQ:WVEBiotechnology
+$0.10 today
- Market cap
- $546.32M
- Beta
- -1.33
- P/E (TTM)
- -6.6
- EPS (TTM)
- -$0.92
Volume 2.21M
Average 4.86M
WVE Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Wave Life Sciences Ltd.NASDAQ: WVE
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses growth accelerates
Q1 FY2026 operating expenses of $69.54M rose 22.4% year over year, ahead of the +15.6% change in trailing-twelve-month operating expenses. Sequentially, it fell 2.7% from the prior quarter. Over 3 fiscal years it compounded at +14.4% a year.
Context
- Operating expenses amounted to 583.4% of revenue in FY2025, up 381.4 pp from a year earlier.
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +22.4% holds above the trailing-twelve-month pace of +15.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 249.26M USD
- Year-over-year change
- +14.0%
- 4-year CAGR
- +10.4%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 249.26M | +14.0% |
| FY2024 | 2024-12-31 | 218.71M | +20.6% |
| FY2023 | 2023-12-31 | 181.3M | +9.0% |
| FY2022 | 2022-12-31 | 166.37M | -1.0% |
| FY2021 | 2021-12-31 | 167.98M | — |
Operating Expenses vs competitors
How WVE compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +15.6% is the 6th highest of 10, against a peer median of +22.3%.
- Operating expenses amounts to 368.0% of revenue for WVE, versus a peer median of 287.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $2.83B USD | +26.4% | +15.3% | 58.9% | |
| LTM Sep 2026 | $1.51B USD | +22.3% | +10.0% | 157.1% | |
| LTM Mar 2026 | $1.4B USD | -27.8% | +14.1% | 64.3% | |
| LTM Sep 2026 | $1.16B USD | +58.1% | +38.7% | 256.5% | |
| LTM Mar 2026 | $319.11M USD | -10.9% | -0.7% | 482.8% | |
| LTM Mar 2026 | $264.22M USD | +15.6% | +14.4% | 368.0% | |
| LTM Mar 2026 | $214.24M USD | +41.4% | +20.6% | 667.8% | |
| LTM Mar 2026 | $130.57M USD | -39.9% | -10.4% | 287.9% | |
| LTM Mar 2026 | $87.2M USD | — | +16.9% | 9463.1% | |
| LTM Mar 2026 | €58.51M EUR | +12.1% | -7.3% | 435.3% | |
| LTM Mar 2026 | $53.82M USD | +43.6% | +32.6% | — | |
| Peer median (excluding WVE) | — | +22.3% | +14.7% | 287.9% | |
Competitors are the stored peer set for WVE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 40.96M | 3.65M | 113.31M | 108.3M | 42.73M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 8.85M |
| Gross Profit | 40.96M | 3.65M | 113.31M | 108.3M | 33.88M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 79.3% |
| Research & Development | 121.88M | 115.86M | 130.01M | 159.68M | 182.78M |
| Selling, General & Admin | 46.11M | 50.51M | 51.29M | 59.02M | 75.33M |
| Operating Expenses | 167.98M | 166.37M | 181.3M | 218.71M | 249.26M |
| Depreciation & Amortization | 9.84M | 10.11M | 9.21M | 8.66M | 8.85M |
| EBITDA | (112.61M) | (151.03M) | (48.98M) | (88.35M) | (195.53M) |
| EBITDA Margin | -274.9% | -4138.9% | -43.2% | -81.6% | -457.6% |
| Operating Income | (127.02M) | (162.72M) | (68M) | (110.4M) | (215.38M) |
| Operating Margin | -310.1% | -4459.3% | -60.0% | -101.9% | -504.1% |
| Interest Income | 30K | 0 | 0 | 0 | 10.48M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4.57M | 1.58M | 9.81M | 13.4M | 11.01M |
| Income Before Tax | (122.45M) | (161.14M) | (58.19M) | (97.01M) | (204.38M) |
| Pre-Tax Margin | -298.9% | -4416.1% | -51.4% | -89.6% | -478.3% |
| Income Tax Expense | (204K) | 681K | (677K) | 0 | 0 |
| Net Income | (122.25M) | (161.82M) | (57.51M) | (97.01M) | (204.38M) |
| Net Margin | -298.4% | -4434.7% | -50.8% | -89.6% | -478.3% |
| EPS (Basic) | (2.36) | (2.05) | (0.54) | (0.70) | (1.21) |
| EPS (Diluted) | (2.36) | (2.05) | (0.54) | (0.70) | (1.21) |
| Weighted Avg Shares | 51.83M | 78.86M | 106.1M | 138.28M | 168.65M |
| Weighted Avg Shares (Diluted) | 51.83M | 78.86M | 106.1M | 138.28M | 168.65M |
Wave Life Sciences Ltd.
NASDAQ:WVE
Intrinsic Alpha fair value
Locked
Current Price
$2.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.